Jun 18, 2020 · 6 min read

Chan Zuckerberg Initiative Awards $2 Million to medRxiv, a Health Sciences Preprint Server and Top Source of Breaking COVID-19 Research

CZI Partners with Cold Spring Harbor Laboratory, Yale University, and BMJ to Help Scientists Share Health and Clinical Research Faster


Editor’s Note: This release has been updated as of 11/2/21.

Today, the Chan Zuckerberg Initiative (CZI) announced $2 million in funding to support medRxiv, a free online repository dedicated to medical, clinical, and health sciences research in the form of preprints, or draft scientific papers. As the top global source of breaking COVID-19 research, medRxiv has posted more than 4,300 preprints related to COVID-19 since January 2020. CZI is partnering with medRxiv to help scientists share health-related research in real time, including critical research about COVID-19 that could inform future treatments.

Researchers around the world are sharing new scientific results on medRxiv and its sister site bioRxiv, the preprint server for biological research, which CZI also funds. The rise of preprints in biomedicine demonstrates how technology and open science are accelerating scientific discovery. Traditionally, it takes anywhere from several months to several years for papers to be drafted, peer-reviewed, and published in a journal. Once published, peer-reviewed results are often only accessible to researchers with journal subscriptions.

The pace and accessibility of research, and their impact on how scientists collaborate, is particularly crucial in the context of infectious disease outbreaks and public health crises. During the Ebola and Zika outbreaks, a study found only about 5 percent of published research papers were shared in the form of a preprint, with most of the relevant papers appearing in journals after the epidemics had subsided. By contrast, over 7,000 preprints related to the COVID-19 pandemic have been posted to a variety of preprint servers in less than six months, with nearly 5,500 of them posted to the independent, not-for-profit bioRxiv and medRxiv platforms.

The potential benefits of rapid sharing of results in the form of preprints go well beyond the scope of outbreak research. “Preprints accelerate science by allowing researchers to share their complete, unpublished manuscripts as quickly as possible, enabling scientists to build off of each other’s results and increase our understanding of health and disease,” said CZI Head of Science Cori Bargmann. “Sharing research results more quickly is especially crucial during the coronavirus pandemic to increase what we know about this virus and our ability to fight it. We are thrilled to continue supporting preprints through bioRxiv and now medRxiv.”

medRxiv was launched in June 2019 as a partnership between Cold Spring Harbor Laboratory (CSHL), Yale University, and global health knowledge provider BMJ. The co-founders are Drs. John Inglis and Richard Sever from CSHL, Professors Harlan Krumholz and Joseph Ross from Yale, and Dr. Theodora Bloom and Claire Rawlinson from BMJ. CZI’s grant to medRxiv will help sustain and scale its screening processes, particularly during significant demand from researchers posting COVID-19-related preprints. It will support the creation of machine-readable content for indexing, discovery, and text and data mining services. In addition, the grant will assist with education and advocacy among authors and readers in medical science for whom preprints are unfamiliar, improve the transparency of the screening process, and develop better guidelines for reporters and science communicators on reporting results that have not been peer reviewed.

“bioRxiv has demonstrated the power of preprints to hundreds of thousands of authors and millions of readers of biomedical research worldwide,” said Dr. John Inglis, co-founder of medRxiv and bioRxiv at CSHL. “In just nine months, medRxiv has surpassed 10 million monthly page views and has a submission rate that took bioRxiv five years to achieve. Clearly, preprints are an extraordinarily valuable resource during this pandemic, but medRxiv’s long-term contribution will be to all clinical disciplines such as oncology, neurology, and genetics — from which submissions have doubled this year.”

As scientific results are shared quickly, scientists are upholding the principles of academic integrity by providing real-time assessment of preprints on bioRxiv and medRxiv, on social media, and through a variety of dedicated projects. These critical evaluations are public demonstrations of the self-correcting nature of science and help diminish the spread of misinformation.

“Preprints have many advantages to traditional publishing — they allow open and rapid dissemination of research; offer novel opportunities for scientific collaboration; and enable new types of community-driven curation and interlinking of results, methods, data, and resources,” said CZI Science Program Officer for Open Science Dario Taraborelli. “Preprint servers like bioRxiv and now medRxiv are changing the nature of collaboration among scientists, and we’re proud to support these partners and the preprint movement.”

Theodora Bloom, Executive Editor, The BMJ said: “As the COVID-19 pandemic intensifies, now, more than ever, health professionals need information quickly. BMJ is a trusted provider of healthcare information, so we’re delighted to be able to bring our expertise to this important enterprise, giving researchers the information they need as soon as it is available. We look forward to continuing to work with our partners in a shared goal to support the scientific community and improve public health and healthcare.”

“With COVID-19, all the rules have changed,” said Dr. Joseph Ross of Yale. “Thousands of scientists are working on the same problem at the same time. It would be such a lost opportunity if scientists were not immediately aware of one another’s work and able to improve, validate, and learn more quickly.”

CZI believes that sharing data, results, open source software, experimental methods, and biological resources as early as possible will advance progress in every area of science. Grantees funded by CZI are required to share their results in the form of a preprint before or by the time of formal submission to a journal. In addition, CZI’s research discovery service Meta, which includes preprints from bioRxiv, now includes preprints from medRxiv. Learn more about CZI’s Open Science program.


About the Chan Zuckerberg Initiative

Founded by Dr. Priscilla Chan and Mark Zuckerberg in 2015, the Chan Zuckerberg Initiative (CZI) is a new kind of philanthropy that’s leveraging technology to help solve some of the world’s toughest challenges — from eradicating disease, to improving education, to reforming the criminal justice system. Across three core Initiative focus areas of Science, Education, and Justice & Opportunity, we’re pairing engineering with grant-making, impact investing, and policy and advocacy work to help build an inclusive, just and healthy future for everyone. For more information, please visit chanzuckerberg.com.

About medRxiv 

medRxiv (pronounced “med-archive”) is a free online platform for complete but unpublished manuscripts (preprints) in the health sciences that gives researchers the opportunity to share and receive feedback on their work. Research articles, systematic reviews and meta-analyses, clinical research design protocols and data articles may be posted. medRxiv is operated by Cold Spring Harbor Laboratory (CSHL), a not-for-profit research and educational institution, in a partnership with Yale University and BMJ, a global healthcare knowledge provider. medRxiv aims to improve the openness and accessibility of scientific findings, enhance collaboration among researchers, document the provenance of ideas, and inform ongoing and planned research through timely reporting of completed research. medRxiv is an independent, non-profit community resource, not linked to any one publisher or journal.

Amazon To Debut CZI-Supported Award-Winning Documentary, "For Love & Life: No Ordinary Campaign"
CZI Launches AI Advisory Group and Residency Program To Accelerate Development of Virtual Cell Models